The fund’s investment objective is to provide a growing income, predominantly from investment in UK equities. In seeking a yield higher than that offered by the major UK equity indices, the fund will invest primarily in above average yielding equities rather than fixed interest securities. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
Name | % Net Assets |
---|---|
AstraZeneca | 6.9% |
Vodafone Group | 5.5% |
Resolution | 5.0% |
BP | 5.0% |
GlaxoSmithKline | 5.0% |
Rentokil Initial | 4.1% |
Morrison Supermarkets | 3.9% |
Lloyds Banking Group | 3.7% |
Royal Bank of Scotland Group | 3.5% |
Barclays | 3.4% |
Key | % Net Assets |
---|---|
AstraZeneca | 6.9% |
Vodafone Group | 5.5% |
Resolution | 5.0% |
BP | 5.0% |
Other | 77.6% |
Date | 31-Oct-2024 |
---|---|
NAV | 12,950.00p |
Currency | GBP |
Change | -60.00p |
% | -0.46% |
YTD change | 1,110.00p |
YTD % | 9.37% |
Fund Inception | 31/05/1987 |
---|---|
Fund Manager | Kevin Murphy / Nick Kirrage |
TER | 1.66 (25-Feb-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.12 |
You are here: research